Aelis Farma

The sponsor focuses on innovative approaches to cannabinoid receptor signaling, specifically targeting the CB1 receptor pathway. Research efforts concentrate on developing selective modulators that can influence endocannabinoid system activity without producing the typical effects associated with cannabinoid compounds. This work represents a novel strategy in cannabinoid pharmacology, aiming to harness therapeutic benefits while minimizing unwanted receptor activation.

• Selective CB1 receptor modulation
• Endocannabinoid system targeting
• Cannabinoid signaling pathways

The therapeutic development emphasizes precision targeting of cannabinoid receptor subtypes to achieve specific pharmacological outcomes in conditions where the endocannabinoid system plays a significant role.